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Abstract:  The  literature  on  hepatitis  B  virus  (HBV)  in  immunocompromised  patients  is 
heterogeneous and refers mainly to the pre
the problem of hepatitis B in these patients provides for: a) the evaluation of HBV mark
and of liver condition in all subjects starting immunosuppressive therapies (baseline), b) the 
treatment  with  antivirals  (therapy)  of  active  carriers, c)  the  pre
(prophylaxis)  in  inactive  carriers,  especially  if  they  are  under
therapies judged to be at high risk, d) the biochemical and HBsAg monitoring (or universal 
prophylaxis in case of high risk immunosuppression, as in onco
bone  marrow  transplantation)  in  subjects  with  marker
(HBsAg-negative  and  antiHBc
Moreover  in  solid  organ  transplants  it  is  suggested  a  strict  adherence  to  the  criteria  of 
allocation  based  on  the  virological  characteristics 
universal prophylaxis or therapy with nucleos(t)ides analogs
Introduction: Hepatitis B virus infection is a major 
public and medical concern. Two billion people are 
overt  carriers  of  HBV  worldwide;  of  them,  360 
million suffer from chronic HBV infection and over 
520,000 die each year, 50,000 from acute hepatitis 
B  and  470,000  from  cirrhosis  or  liver  cancer. 
Moreover  many  subjects  have  on
previous  contact  with  the  HBV  (antiHBc+/
antiHBs),  which  can  indicate  an  Occult  HBV 
Infection (OBI).
Immunodepression  due  to  the  underlying 
disease  or  to  drugs  used  in  immunosuppressive, 
anticancer  therapy  and  in  organ  transplants  can 
influence the hepatitis B virus (HBV), both in terms 
of reactivation and in terms of the acceleration of a 
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The  literature  on  hepatitis  B  virus  (HBV)  in  immunocompromised  patients  is 
heterogeneous and refers mainly to the pre-antivirals era. Currently, a rational approach to 
the problem of hepatitis B in these patients provides for: a) the evaluation of HBV mark
and of liver condition in all subjects starting immunosuppressive therapies (baseline), b) the 
treatment  with  antivirals  (therapy)  of  active  carriers, c)  the  pre-emptive  use  of  antivirals 
(prophylaxis)  in  inactive  carriers,  especially  if  they  are  undergoing  immunosuppressive 
therapies judged to be at high risk, d) the biochemical and HBsAg monitoring (or universal 
prophylaxis in case of high risk immunosuppression, as in onco-haematologic patients and 
bone  marrow  transplantation)  in  subjects  with  markers  of  previous  contact  with  HBV 
negative  and  antiHBc-positive),  in  order  to  prevent  reverse  seroconversion. 
Moreover  in  solid  organ  transplants  it  is  suggested  a  strict  adherence  to  the  criteria  of 
allocation  based  on  the  virological  characteristics  of  both  recipients  and  donors  and  the 
universal prophylaxis or therapy with nucleos(t)ides analogs
Hepatitis B virus infection is a major 
concern. Two billion people are 
overt  carriers  of  HBV  worldwide;  of  them,  360 
million suffer from chronic HBV infection and over 
520,000 die each year, 50,000 from acute hepatitis 
B  and  470,000  from  cirrhosis  or  liver  cancer. 
Moreover  many  subjects  have  only  markers  of 
previous  contact  with  the  HBV  (antiHBc+/-
antiHBs),  which  can  indicate  an  Occult  HBV 
Immunodepression  due  to  the  underlying 
disease  or  to  drugs  used  in  immunosuppressive, 
anticancer  therapy  and  in  organ  transplants  can 
nce the hepatitis B virus (HBV), both in terms 
of reactivation and in terms of the acceleration of a 
pre-existing chronic hepatitis. In this situation the 
possibility  of  HBV  relapse  has  been  known  for 
years,  with  clinical  manifestations  ranging  from 
selflimiting  anicteric  to  fulminant  forms  or  to 
chronic hepatitis with an accelerated clinical course 
towards  liver  decompensation.  Hepatitis  reacti
vation  may  influence  the  continuation  of  the 
specific  treatments  and  the  survival  of  immuno
depressed or transplanted patients
The risk of clinical events is mainly observed in 
overt carriers of HBV, but can also develop in the 
OBI condition which has been widely described in 
the literature of the last decade.
Progress  in  the  diagnostic  procedu
various virological conditions associated with HBV, 
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The  literature  on  hepatitis  B  virus  (HBV)  in  immunocompromised  patients  is 
antivirals era. Currently, a rational approach to 
the problem of hepatitis B in these patients provides for: a) the evaluation of HBV markers 
and of liver condition in all subjects starting immunosuppressive therapies (baseline), b) the 
emptive  use  of  antivirals 
going  immunosuppressive 
therapies judged to be at high risk, d) the biochemical and HBsAg monitoring (or universal 
haematologic patients and 
s  of  previous  contact  with  HBV 
positive),  in  order  to  prevent  reverse  seroconversion. 
Moreover  in  solid  organ  transplants  it  is  suggested  a  strict  adherence  to  the  criteria  of 
of  both  recipients  and  donors  and  the 
existing chronic hepatitis. In this situation the 
possibility  of  HBV  relapse  has  been  known  for 
years,  with  clinical  manifestations  ranging  from 
miting  anicteric  to  fulminant  forms  or  to 
chronic hepatitis with an accelerated clinical course 
towards  liver  decompensation.  Hepatitis  reacti-
vation  may  influence  the  continuation  of  the 
specific  treatments  and  the  survival  of  immuno-
nted patients
1.
The risk of clinical events is mainly observed in 
overt carriers of HBV, but can also develop in the 
OBI condition which has been widely described in 
the literature of the last decade.
2
Progress  in  the  diagnostic  procedures  of  the 
various virological conditions associated with HBV, Medit J Hemat Infect Dis 2010; 1(3); Open Journal System 
Table 1. Virological categories
Acrive carrier Inactive carrier AntiHBc-positive (anti-core)
HBsAg Positive Positive Negative
HBeAg Positive or negative Negative Negative
AntiHBs Negative Negative Positive or negative
AntiHBc Positive Positive Positive
ALT
b
Persistently or intermittently 
increased Persistently normal
c Persistently normal
c
HBV DNA serum ≥ 20.000-2.000
a IU/ml < 20.000 IU/ml Negative (>90%)
HBV DNA tissue Positive Positive Positive
Liver damaged yes (>90%) no (>90%)
c no
c
a In anti-HBe positive patients, 
b Alanine aminotransferase, 
c In the absence of other causes of chronic hepatits and/or of a previous 
history of chronic hepatits B, 
d Necroinflammatory score >4 HAI
the  recent  availability  of  effective  antiviral 
treatments,  the  growing  incidence  of 
immunocompromised  patients  attributable  to  the 
evolution  of  immunosuppressive  therapies  and 
organ  transplants  and  the  expectation  of  an 
important future increase of HBV reactivation have 
brought  this  problem  to  the  fore,  although  the 
rational approach and management of these patients 
is still debated.
Definitions
Virological  characteristics:  Persistent  HBV 
infection is defined as overt when the hepatitis B 
surface  antigen  (HBsAg)  is  present  in  amounts 
well-detectable  by  sensitive  immune  assays  and 
occult in HBsAg-negative subjects with evidence of 
intrahepatic  and/or  serum  HBV  DNA.
2 In  occult 
carriers,  HBsAg  can  be  completely  absent  (real 
OBI)  or undetectable  for  very  low  amounts  or 
polymorphisms (false OBI).
A.  HBV  carriers  (HBsAg-positive).  In 
accordance with the international definitions, they 
can be identified as: 1) active carriers, in presence 
of HBeAg or of anti-HBe antibodies and of a viral 
load ≥ 2-20,000 IU/ml; this condition is associated 
with the presence of hepatic disease in the most part 
of cases, or 2) inactive carriers,in case of subjects 
HBeAg-negative  and  antiHBe-positive,  whose 
alanine  aminotransferase  (ALT)  levels  are 
persistently  within  the  normal  range,  HBV  DNA 
below 2,000 IU/ml in  the most part  of cases and 
IgM  antiHBc  levels  <  0.20  IMx  Index.  In  the 
majority of these subjects the histological finnding, 
when available, does not reveal a significant liver 
disease  (necro-inflammatory  activity  <  4  HAI), 
while in a small minority of cases it is possible to 
observe the effects of a chronic liver disease which 
became silent spontaneously or following antiviral 
treatment
3,4.
B. Occult HBV carriers (HBsAg-negative).The 
difficulty  in  determining  HBV  DNA  in  the  liver 
biopsy (frequently not justified in subjects without 
clinical  signs  of  hepatitis),  the  rare  presence  of 
detectable  viremia  in  serum  even  with  sensitive 
techniques,  and  the  frequent  presence  in  occult 
carriers  of  markers  of previous  contact  with  the 
HBV (antiHBc+/- antiHBs), leads one to consider 
all anti-HBc (anti-core)-positivesubjectsas potential 
occult  carriers.  Instead  there  are  no  serum 
determinants in the minority (about 20%) of occult 
carriers who are negative for all HBV markers.
Virological  events:  In  HBV  carriers  (occult  or 
overt)  the  following  virological  events  are 
considered significant: 1) in anti-core subjects the 
reemergence  of  HBsAg(sero-reversion),  2)  in 
inactive  carriers  the  appearance  of  a  significant 
viremia  (≥20,000  IU/ml)  (reactivation),  as  this  is 
frequently  associated  with  liver  damage  due  to 
HBV,  3)  in  active  carriers  the  persistence  of  a 
significant  viremia  (>  20,000  IU/ml  in  HBeAg 
positive  patients  and  >  2,000 IU/ml  in  HBeAg 
negative  subjects)  (activity),  as  this  is  frequently 
associated with progression of liver damage due to 
HBV, 4) in all the virological categories (whether or 
not during prophylaxis or therapy with antivirals), 
the increase in at least one logarithm of HBV DNA, 
compared  to  its nadir,  reconfermed  in  two 
consecutive serum  tests  during  monitoring 
(virologic breakthrough) (Table 1)
4.
Clinical  definitions:  The  assessment  of  chronic 
liver  disease  is  the  fundamental  event  of  the 
diagnostic picture (baseline) (Table 2) and requires 
the use  of  all  the  instruments  usually  utilised  in 
hepatology including, if necessary, trans-cutaneous 
or  trans-jugular  liver  biopsy  in  subjects  with 
coagulation  problems  (for  example  patients  with 
blood or kidney diseases).
The baseline diagnosis of the disease is pivotal 
in the choice of which treatment to adopt, as the risk Medit J Hemat Infect Dis 2010; 1(3); Open Journal System 
Table 2. Baseline assessment
Level 1 Level 2 Level 3
Patients with 
altered 
transaminase
Patients HBsAg-
positive
Patients Anti-core 
positive
Patients HBV DNA-positive and/or 
with chronic hepatitis
Transaminase  upper abdomen HDV AntiHBe IgM antiHBc (Imx index)
Colestasis index US HBV DNA PCR Liver biopsy assessment
Hemochrome Glycemia HBeAg, AntiHBe
Total and 
fractionated bilirubin Lipidic profile HBV DNA PCR
AntiHCV INR
HBsAg, AntiHBs 
titer, AntiHBc Ferritin
US ultrasound, INR: International Normal Ratio, PCR: Polymerase Chain Reaction
of severe complications is related to the severity of 
the underlying liver disease
5.
In  order  to  standardize  the  deÞ  nitions  the 
following terms  were suggested:  1) infection  (not 
necessarily associated with reactivation of hepatitis) 
in  the  case  of  the  detection  of  HBV  DNA  by 
sensitive HBV assays and/or of HBsAg in patients 
in whom these markers were originally negative, 2) 
reactivation  of  hepatitis  B  (hepatitis),  in  the 
presence  of a  significant viremia and  ALT  levels 
above the upper normal value.
Treatment Strategies: The term prophylaxis was 
used to mean treatment with antiviral drugs of an 
inactive  or  occult  infection,  with  the  aim  of 
preventing  hepatitis  reactivation.  Prophylaxis  was 
defined as:  1) universal prophylaxis  (UP), if  it is 
carried out  on the  entire population potentially at 
risk  (inactive  carriers  and/or  anti-core),  2)  or 
targeted prophylaxis (TP), if it is subordinate to the 
appearance of infection markers (HBV DNA and/or 
HBsAg)  in  the  absence  of  hepatitis  reactivation 
(Table 3). Therapy (T) was understood to mean the 
treatment  of  hepatitis B  (i.e.  chronic  hepatitis  in 
active carriers or hepatitis reactivation)
Treatment Options: In Italy the  following drugs 
are available at present: interferons, either standard 
or peghilated (both little tolerated in the condition 
of  immunodepression,  especially  in  transplant 
patientsfor the potential risk of rejection)  and the 
nucleos(t)ides  analogs(NAs),  which  currently 
include  lamivudine,  adefovir-dipivoxil  ,  entecavir, 
telbivudine and tenofovir and and emtricitabine for 
patients with HBV-HIV co-infection.
In  naive  patients  lamivudine,  which  has  a 
considerable antiviral effect, frequently (50-60% at 
4 years, low genetic barrer) induces the selection of 
lamivudine-resistant mutants in locus YMDD of the 
polymerase  gene  (YMDD).  However, adefovir-
dipivoxil  has  a  low  antiviral  effect  but  induce  a 
lower selection of  mutants, while Telbivudine  is 
more  potent  with  an  intermediate  genetic  barrer. 
Finally,  third  generation  NAs  (Entecavir  and 
Tenofovir)  have  both  a  high  potency  and  a  high 
genetic barrer
3.
Data from experience in liver transplanted and 
HIV  patients  have  shown  a  relation  between  the 
original viremia, the degree of immunosuppression 
and  the  selection  of  mutants  during  prophylaxis 
with  lamivudine.
9,10 Consequently  a  careful 
monitoring of the response to treatment and of the 
resistance  is  suggested  in  immunocompromised 
patients treated with Nas.
Hereafter    are  reported  the  statements  of  the 
Italian  guidelines  referred  to  hepatitis  B  and 
recently  updated  with  a  special  attention  to  the 
different therapeutic options available nowadays.
8
Screening.  It  is  recommended  that  all 
immunocompromised patients and  those candidate 
to  chemotherapy,  immunosuppressive  therapy 
and/or  transplantion  are  screened  for  HBsAg  and 
anti-HBc.  Seronegative  patients  should  be 
vaccinated  preferibly  with  a  reinforced  course  of 
vaccination  for  the  diminished  vaccinal  response 
linked to the immunocompromission.
Chronic  carriers  with  active  HBV  replication 
(HBV  DNA >  2.000  IU/mL).  They  should  be 
treated  as immune-competent patients. NAs are the 
first  choice,  regardless  of  the  clinical  settingMedit J Hemat Infect Dis 2010; 1(3); Open Journal System 
Table 3. Treatment Strategies
Clinical 
Condition
Original virological condition
Active carriers Inactive carriers or anti-core positive
Infection  yes Yes Yes
Hepatitis yes No Yes
Treatment Therapy Prophilaxis therapy
All the population Only in pateints with infection 
markers
a
Universal Targeted
a Infectiona markers: evidence of HBV DNA or HBsAg in serum in originally negative patients
(oncology,  haematology,  rheumatology, 
nephrology,  gastroenterology,  dermatology,  solid 
organ  transplantation).  Pegylated  interferon  is 
contraindicated  in  most  cases.  NAs  with  high 
potency and low resistance should be used, such as 
Entecavir  or  Tenofovir.  Telbivudine  could  be 
considered in those with HBV DNA < 2,000,000 
IU/ml. 
Close  virologic  monitoring    is  mandatory 
during    immunosuppression.  The  addition  of  a 
second drug (a nucleotide in patients treated with a 
nucleoside and vice versa) is advisable in cases of 
incomplete  virologic  response,  or  primary  non-
response to monotherapy. In immunocompromised 
patients  the  dose  of  NA(s)  should  be  adjusted 
according to the renal function, co-morbidities and 
drugs interactions. 
Inactive  HBsAg  carriers  (HBV  DNA 
persistently < 2,000 IU/ml). In patients undergoing 
solid  organs transplant or autologous or allogenic 
bone marrow transplantation or high risk immune 
suppressive  treatment  (anti-TNF,  anti-CD20,  anti-
CD56, medium/high dose of steroids  (>10 mg/die) 
for  prolonged  periods,  ciclofosphamide, 
metotrexate, leflunomide, cyclosporine, tacrolimus, 
azathioprine  and  micofenolate)  antiviral 
prophylaxis  with  a  NA  is  recommended,  starting 
from  the  beginning  of  the  immune-suppressive 
treatment or preferibly 2-4 weeks before. In other 
conditions patients should be  only monitored for 
HBV DNA reactivation. 
If the duration of immunosuppressive therapy is 
limited,  the  pharmacologic  risk  of  resistence  is 
diminished;  therefore  a  low  cost  NA,  such  as 
Lamivudine,  may  be  used.  In  patients  who  need 
prolonged  immunosuppression  the  use  of  more 
potent NAs at lower risk to induce resistance can be 
considered). 
HBsAg-negative, anti-HBc positive patients. In 
these  subjects  HBV  DNA  should  be  tested  at 
baseline in order to distinguish real from false OBI. 
Viremic HBsAg-negative patients should be treated 
with  a  NA.  Anti-HBc  positive  subjects  with 
haematological  diseases  undergoing  strongly 
immunosuppressive treatments such as: fludarabine, 
dose-dense regimens, autologous or allogenic bone 
marrow  transplant,  treatment  with  monoclonal 
antibodies (anti – CD-20 and anti CD52) should be 
treated with a NA (preferably Lamivudine for short 
term  therapies),independently  of  anti- HBs 
reactivity.
Anti-HBc  positive  patients  in  other  clinical 
settings  should not be treated but only monitored 
for  liver  enzymes  and  the  emergence  of  serum  
HBsAg every  1-3  months.  Some  experts 
recommend  prophylaxis  with  a  NA  also  in  non-
haematological patients if they are treated with anti-
CD20.   
Monitoring During Therapy: Once NAs therapy 
or  prophylaxis  has  been  started,  monitoring  will 
essentially be through testing serum HBV DNA and 
ALT  levels  every  three  months,  to  assess:  1) 
response to treatment (i.e. reduction of HBV DNA, 
preferably  below  the  limit  of  sensitivity  of  the 
amplified techniques and ALT normalization) and 
2) drug-resistance, which should be suspected in the 
case  of virologic breakthrough while  ontreatment, 
in  order  to  activate  an  early  rescue  therapy
3,11. 
Resistance can be defined clinically by the virologic Medit J Hemat Infect Dis 2010; 1(3); Open Journal System 
breakthrough4  but    a  genotypic  testing  is 
reccomended and should be used in order to better 
define  the  different  mutations  and  to  choose  the 
rescue therapy
3,8.
Impact  on  Different  Specialist  Fields:  Data 
regarding  hepatitis  B  in  immunocompromised 
patients are very heterogeneous. As a result there is 
a  strong  indication  to  promote  studies  aimed  at 
defining the natural history of hepatitis B in these 
patients, to assess – also prospectively - different 
treatment  protocols  and  to  promote  close 
cooperation among different specialists.  
Oncology, Hematology and Hematopoietic Stem 
Cell Transplantation (HSCT)
Background: During chemotherapy hepatitis B can 
make  its  appearance  in  two  different  phases:  1) 
during the treatment, in relation to the intense bone 
marrow  suppression,  which  is  associated  with  a 
strong  viral  replication  and,  sometimes,  with  the 
emergence of a fulminant hepatitis in the form of 
fibrosing cholestasis, 2) after the end of therapy, as 
during  the  immuno-reconstitution  phase  the 
immune  response  can  bring  on  a  reactivation  of 
hepatitis whose clinical course may be more or less 
severe depending on the baseline condition of the 
liver and other possible factors that may contribute 
to the damage.
In oncology the prevalence of HBsAg-positive 
patients ranges between 5.3% (in Europe) and 12% 
(in  China).  In  these  patients  the  frequency  of 
clinical  HBVreactivation  ranges  between  20  and 
56%,  correlating  with  the  use  of  steroids, 
anthracyclines,  5-fluouracil  with  some  virological 
indicators  (presence  of  HBeAgor  of  e-minus 
variants and/or of a detectable HBV DNA prior to 
therapy).  Theclinical  significance  of  relapse  has 
been clearly associated with the pre-chemotherapy 
liver function, with a mortality of 5-40%. 
The  reactivation  of  hepatitis,  moreover, 
influences  the  continuation  of  the  chemotherapy, 
inducing its suspension and not infrequently posing 
problems  of  differential  diagnosis  with  regard  to 
drug toxicity. Hepatitis B can develop both in active 
and in inactive carriers and it is generally associated 
with the reappearance of a significant viremia in the 
preceding 2-3 weeks.
In hematology the frequency of HBsAg positive 
patients is higher (12.2% in Greece and 8.8% in a 
recent study from Italy) and the risk of reactivation 
appears  to  be  greater  than  in  other  settings  of 
oncology,  depending  on  the  degree  of 
immunosuppression. In this setting, control of the 
HBV infection assumes great importance in order to 
prevent HBV-related complications, but also so as 
not  to  modify  a  highly  successful  therapeutic 
schedule.In this field the main prognostic indicators 
unfavorably associated with hepatitis B reactivation 
are,  besides  those  already  cited,  hyper-
transaminasemia  and  the  condition  of  second  or 
third cycle compared to the first
1,12- 14. 
In hematology, a 21-67% (median 50%) risk of 
reactivation  has  been  described,  with  an  average 
mortality  of  20%.  In  this  setting,  the  available 
literature  is  not  clear  whether  the  severity  of 
hepatitis in HBsAg-positive patients is directly due 
to the liver damage caused by HBV reactivation or 
by other causes (i.e. VOD, GvHD or MOF) and also 
the  degree  of  risk  in  relation  to  the  condition  of 
active or inactive carrier is not clearly determinable.
The risk would appear to be heightened by the 
use  of  monoclonal  antibodies  (antiCD20, 
antiCD52),  with  the  possibility  of  hepatitis 
reactivation  (even  after  a cycle  of  1-3 months  of 
prophylaxis with lamivudine) at a variable distance 
from  the  last  administration  of  these  drugs, 
particularly in overt carriers, but also in anti-core 
subjects. An analogous risk exists in the course of 
allogeneic HSCT, as the immuno-suppressive effect 
in the conditioning phase is particularly strong and 
is  amplified  by  the  subsequent  anti-rejection 
therapy, so the risk of hepatitis reactivation remains 
throughout the phase of immuno-reconstitution (in 
some cases until 1-2 years from transplantation)
1,15-
17,45.
Experiences in the different virological categories:
1. Active  HBsAg-carriers:  In  the  onco-
hematological  setting  lamivudine  therapy  of 
chronic hepatitis in active carriers appears to be 
effective.1
2. Inactive  HBsAg-carriers:  The  start  of 
lamivudine therapy at the time of the clinical 
relapse (hepatitis) in inactive carriersmaintains 
a residual mortality of 20%, probably in relation 
to  the  baseline  conditions  and  to  the  delayed 
treatment.
However,  in  retrospective  studies  lamivudine 
has been shown to be effective in prophylaxis 
of  hepatitis  B  (0-9%  of  hepatitis  reactivation 
compared to 25-85% in untreated patients) and 
in the only prospective study hepatitis relapse 
developed in 5% of treated subjects and in 24% 
of controls. Moreover, in the study the universal 
use of lamivudine was better than the targeted 
prophylaxis (activated only at the appearance of 
HBV  DNA  with  a  non-amplified  technique, Medit J Hemat Infect Dis 2010; 1(3); Open Journal System 
during bimonthly monitoring), both in terms of 
survival  and  of  hepatitis  reactivation  (0% 
vs.53%, P=0.002)
1,17,18,49,50.
Recently  many  meta-analyses  have  confirmed 
the  signficant  efficacy  of  lamivudine  in 
preventing  hepatitis  B  in  HBsAg  positive 
patients,  in  reducing  deaths  and  in  reducing 
chemotherapy discontinuation.
Finally,  as  lately  reported  in  literature, 
lamivudine-prophylaxis in  HBsAg-positive 
patients  undergoing  chemotherapy  has  been 
shown  to  be  cost-effectivein  terms  of  HBV 
reactivation  (9.6%  LAM+  vs.  43.8%  LAM-), 
liver  related  deaths  (0/500  LAM+  vs  20/500 
LAM-),  chemotherapy  discontinuation  and 
cancer  deaths (39/500  LAM+  vs 47/500 
LAM-)
46-48.
3.  Anti-core  patients  (HBsAg-negative):  In  the 
oncological  setting  there  are  few  data,  at 
present, for this virological category, which can 
reach 20-40% in averagely endemic areas and 
70-80%  in  highly  endemic  areas.However,  in 
the hematological setting, out of a total of 176 
patients  described  in  literature,  sero-reversion 
has been reported in 21 subjects (12%) during 
conventional chemotherapy, whether or not this 
was associated with HSCT, with percentages of 
4-30% during chemotherapy and 14-50% in the 
course of autologous transplantation.
After autologous HSCT, hepatitis B developed 
in anti-HBc patients later (6-52 months, average 
19 months) than in overt carriers (average 2-3 
months) and none of the patients described died 
of hepatitis B (in 7 cases during therapy with 
lamivudine, started  at  the time  of  the  clinical 
relapse). After the reactivation nine of the 10 
patients remained HBsAg positive and one lost 
the  HBsAg  during  follow-up.  Instead,  two 
deaths  out  of  39  subjects  with  seroreversion 
have been reported in literature after allogeneic 
HSCTand  this  appeared  to  have  been 
significantly linked to the absence of protective 
antibodies  (antiHBs)  in  the  donor  and  to 
GVHD
1.
Recently  the  introduction  in  hematologic 
treatments  of  monoclonal  anti-lymphocyte  B 
and  T  antibodies  (anti-CD20  and  anti-CD52), 
used alone or together with chemotherapy, has 
been associatedwith the signaling of some cases 
of  sero-reversion  in  anti-core  subjects, 
sometimes with a fulminant form and death of 
the patients, despite therapy with lamivudine
1.
HBV  infection  has  been  described  to  be  the 
most  frequently  (39%)  experienced  viral 
infection  in  lymphoma  patients  treated  with 
Rituximab. In a study about 50% of Rituximab-
related  HBV  infections  resulted  in  death, 
whereas this was the case in only 33% of the 
patients with other infections.
An Italian study has lately stressed a very low 
(1%)  overall  risk  of  sero-reversion  in  a  large 
series of patients treated for lymphoma, but the 
risk  of  hepatitis  B  reactivation  was  3.5  fold 
increased for
Rituximab  therapy,  compared  to  conventional 
chemotherapy (P < 0.005). Data confirming the 
increased risk of HBV reactivation in patients 
undergoing  anti  B-cell  therapy  have  also 
emerged  in  a  trial  which  showed  as 
alemtuzumab containing chemotherapy regimen 
was  associated  with  a  high  risk  (29%)  of 
reactivation  of  occult  HBV  infection  and  of 
severe HBV-related hepatitis
51-54.
Recommendations from the Italian guidelines: 
1. In active carriers therapy is considered useful 
to  control  the  liver  disease  pre- and  post-
immunosuppressive  treatments.  In  HSCT,  in 
particular,  the  control  of  the  HBV-related 
disease  permits  a  more  precise  diagnosis  and 
treatment  of  specific  liver  complications 
(GVHD and VOD). In these patients, antiviral 
therapy should be continued lifelong (due to the 
high risk of relapse after withdrawal) or at least 
until the disappearance of HBsAg in serum. A 
strict  monitoring  of  mutants  should  be 
activated, in order to prevent hepatitis relapse 
with rescue therapy.
2. In  the  inactive  carriers  universal  prophylaxis 
appears to be indicated and should be continued 
for the entire phase of chemotherapy, until at 
least  12-18months    after  the  end  of  the 
treatment.1,18  The  optimal  duration  of  the 
prophylaxis  is  still  debated  and  requires 
prospective  studies.  In  any  case,  it  is 
recommended  the  monitoring  of  the  viremia 
after suspension, for the prompt diagnosis and 
return to treatment in the case of reactivation.
3. In  anti-HBc  positive  (HBsAg-negative) 
patients,  two  different  strategies  can  be 
identified:  a)  in  oncology  or  in  patients 
undergoing  mild  hematological  therapies 
(judged  to  be  at  low  immunosuppressive 
potential, such as the ABVD of the CHOP 21 
days  scheme),  HBsAg  monitoring  every  1-3 
months  is  advised,  with  the  activation  of 
targeted prophylaxis or therapy in the case of 
sero-reversion  or  hepatitis  reactivation, Medit J Hemat Infect Dis 2010; 1(3); Open Journal System 
respectively.  However,the  use  of  HBV  DNA 
monitoring  for  targeted  prophylaxis  remains 
controversial  because  of  the  lack  of  data 
referred  to  the  timing  and  duration  of  the 
monitoring  and  to  the  clinical  significance  of 
minimal  levels  of  detectable  viremia  (i.e.  the 
presence of low levels of serum HBV DNA in 
OBI carriers  after solid organs transplantation 
has  rarely  a  clinical  impacts  and  is  not 
constantly  associated  with  hepatitis  relapse)
19.
b)  In  subjects  who  need  to  be  treated  with 
intense  immunosuppression (chemotherapy 
with  fludarabine,  dose-sense  regimes, 
allogeneic transplant, autologous myeloablative 
transplant, induction in acute leukemia, use of 
monoclonal antibodies) universal prophylaxis is 
proposed.
This  approach  is  strongly  indicated  in  the 
hematological setting and in patients with signs of a 
chronic hepatitis (due to a previous history of HBV-
related  disease  and/or  to  other  causes  of  chronic 
hepatitis) and/or with a positive serum HBV DNA 
and/or  positive for  antiHBe  antibodies  at  the 
baseline evaluation. 
Effects  of  different  virological  conditions  in 
donors  (D)  and  recipients  (R)  of  Allogeneic 
Hematopoietic  Stem  Cell  Transplantation 
(HSCT): 
1. D  HBsAg-/antiHBs+/antiHBc±)->R 
(HBsAg+):In  the  case  of  transplant  from  an 
immunized (antiHBs-positive) donor to an overt 
carrier (HBsAg-positive) recipient two possible 
scenarios have been described: a) the chance of 
adoptive transfer of immunity with the possible 
clearance of HBsAg (especially if recipients are 
treated  with  lamivudine),  b)  an  acute  and 
sometimes  fulminant  hepatitis  (in  historical 
series)
1.
2. D  (HBsAg-/antiHBs±/anti-HBc+)->R  (HbsAg-
/antiHBs±/anti-HBc ±):  Only  few  data  are 
available,  indicating  that  in  the  case  of 
transplant from an anti-HBc positive  donor the 
risk  of  sero-reversion  in  the  recipient  would 
appear  to  be  negligible  in  both  anti-HBc 
positive and negative  recipients
21.
3. D (HBsAg+).>R (HBsAg-): In a few studies, 
transplant from an HBsAg-positive donor was 
associated  with  hepatitis  in  44-62%  of 
recipients, with generic hepatic mortality in 33-
75% of cases, although the role of HBV in these 
clinical  events  was  not  well  defined.  In  a 
historical retrospective  multicenter  study 
performed in the pre-antiviral phase, the anti-
HBV  specific  immunoglobulins  (HBIG)  were 
not  protective  against  the  transmission  of  the 
infection.  In  contrast,  in  a  recent  study  the 
activation of therapy with lamivudine in donors 
and  of prophylaxis with the  same antiviral in 
recipients  significantly  reduced  the  HBV-
related hepatitis rate (48 vs. 7%, P=0.002) and 
mortality (24  vs. 0%,  P=0.01)  compared to  a 
historical control group
1. Furthermore two case 
reports  have  confirmed  the  efficacy  of 
lamivudine-prophylaxis  in  this  clinical  setting 
in preventing HBV related hepatitis
55,56.
General recommendations in HSCT: 
● Vaccination of the recipient prior to transplant, 
if  possible,  with  accelerated  protocols, 
(recombinant  vaccine  40  µg  by  intramuscular 
route,  time  0-1-2  months  or  0-7-21  days), 
especially if he/she is naïve.
● Vaccination of the donor not immunized prior 
to  transplant,  with  accelerated  protocols 
(recombinant  vaccine  20  µg  by  intramuscular 
route time 0-1-2 months or 0-7-21 days) in the 
case of allogeneic HSCT.
● Treatment  of  the  HBsAg-positive  donor  with 
lamivudine  pre- HSCT  in  order  to  reduce 
infectivity  through  the  reduction  of  viremia 
(preferably below the limit of sensitivity of an 
amplified  assay)  and  universal  prophylaxis  of 
the recipient on the day before the transplant.
● The  use  of  high  doses  of  HBIG  (intravenous 
10,000  IU)  during  infusion  of  hematopoietic 
stem cells from overt carriers (who have been 
preventively treated with antivirals) in HBsAg-
negative recipients remains controversial. 
Because of the actual results of the hepatologic 
and hematologic therapy there is no reason to deny 
hematopoietic  stem  transplantation  from  an  HBV 
positive donor (any form) if the risk-benefit ratio is 
in favor of transplantation. Moreover in the case of 
an  HLA  identical  family  HBV  positive  member 
there is no point in wasting time and resources in 
searching for an unrelated donor in the international 
bone marrow donor bank.
Dialysis and Solid Organs Transplants (Kidney, 
Heart and Lung)
Background:  Dialysis: The  incidence  of 
overtcarriers of HBsAg among dialyzed patients is 
0-7%  in  developed  countries  and  10-20%  in 
developing  ones.  In  these  subjects  the  frequent 
normality  of  the  transaminase  makes  clinical 
judgment difficult, confirming the fundamental role 
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and of the liver biopsy to distinguish between active 
and inactive carriers (baseline). In this setting data 
about the condition of OBI carrier among anti-HBc 
patients are scarce and consider the sole presence of 
viremia  in  serum,  whose  diagnostic  sensitivity  is 
low.
In  kidney  transplant  the  condition  of  HBsAg 
carrier can be estimated in 10-20% of cases and is 
associated with a significantly higher risk of death 
(OR  2.49,  95%  CI),  independent  of  the  viremic 
condition  (active  or  inactive  carrier),  and  the 
chronic  hepatitis  presents  an  accelerated  course 
towards  cirrhosis  (5.3-12%-year), decompensation 
and hepatocarcinoma
23,24.
In  heart  and  lung  transplant,  Italian  reports 
have  signalled  HBsAg  positivity  in  2.3-3.7%  of 
recipients. In this setting the evolution of the HBV-
related disease is accelerated in active carriers and 
the risk of hepatitis B reactivation post-transplant is 
over 50% in originally inactive subjects. Finally, the 
risk of sero-reversion postsurgery (de-novo hepatitis 
B) in HbsAg-negative/anti-HBc positive recipients 
seems to be lower than 5%
25-27.
Clinical experiences in nephrology: No controlled 
trials  for  the  treatment  of  HBV  with  either 
interferon or lamivudine in dialyzed patients or in 
kidney transplants are currently available. Interferon 
can be used to treat dialyzed patients with chronic 
hepatitis B, but it is contraindicated in transplanted 
patients.  Short-term  administration  of  lamivudine 
monotherapy  is  effective  but  when  the  drug  is 
withdrawn, viremia rebounds and hepatitis relapses 
in  most  cases.  Continuous  administration  of 
lamivudine monotherapy for 3 to 4 years is able to 
obtain  long-term  suppression  of  HBV  replication 
and may prevent the development of liver related 
complications and mortality
28. Secondary treatment 
failure  is  caused  by  the  emergence  of  YMDD 
which, in some patients, herald hepatitic flares and 
progression of the liver disease.
Recommendations  in  relation  to  transplant 
recipients from the Italian guidelines: 
1. Active carrier: In candidates for kidney, heart 
or lung transplant the indication to therapy is 
confirmed, both in the pre-transplant (with NAs 
or interferons, when they are tolerated) and in 
the post-transplant phase (only NAs in view of 
the high risk of interferon-induced rejection).
2. Inactive  carrier: Pre-transplant  and  during 
dialysis  there is  no indication for  prophylaxis 
but  biochemical  and  virological  monitoring is 
advised, if the diagnosis has been confirmed by 
strict adherence to previously defined criteria. 
Instead,  therapy  should  be  used  in  the  re-
activated  forms  (HBV  DNA  >20,000  IU/ml), 
especially  if  associated  with  significant  liver 
damage  (HAI  >  4  and/or  signs  of  Þ  brotic 
disease  by  non-invasive  methods).  Post-
transplant,  however,  there  is  an  indication  to 
universal prophylaxis,in relation to the available 
data  on  mortality  in  HBV  carriers, 
independently  from  their  virological 
condition.
23
3. Anti-HBc positive  recipient: In these  recipients 
of  kidney,  heart  and  lung  transplant  the 
presence  of  subclinical  manifestations  (low 
levels of circulating HBV DNA detectable with 
very  sensitive    techniques  post-transplant) 
without  sero-reversion  in  over  95%  of 
cases
19,23,24,27  has  been  indicated.In  this 
condition  only  monitoring of  the  HBsAg  is 
required,  with  the  activation  of  targeted 
prophylaxis or therapy onlyin the case of sero-
reversionand/or hepatitis, respectively.
Recommendations  in  relation  to  transplant 
donors: 
1.  Anti-HBc positive donors: In the case of kidney, 
heart  or  lung  allocation  from  an  HBsAg-
negative/anti-HBc  ositive/antiHBs-positive  or 
negative donor in a HBsAg-negative recipient, 
the risk of hepatitis B appears to be less than 
5%
27,29. The low risk does not justify preventive 
prophylaxis, but only HBsAg monitoring (every 
3-6 monthsand/or in  the  case  of transaminase 
increase) and the use of targeted prophylaxis or 
therapy only in the case of sero-reversion. 
2. HBsAg-positive  donors: In  this  condition  the 
risk  of  transmission  of  the  HBV  infection  is 
very  high  in  the  absence  of  prophylaxis, 
especially  from  HBeAg-positive  donors.
30
Recently some reports have indicated the post-
transplant  control  of  hepatitis  B  in  HBsAg-
negative/antiHBs-positive  recipients  of  organs 
from  HBsAg-positive  donors,  while  on 
lamivudine prophylaxis
31.
Liver Transplantation
Background:  The  risk  of  post  transplantation 
hepatitis B is strictly influenced from both recipient 
and donor virological characteristics:
a)  HBsAg-positive recipients: in the absence of pre-
and postoperative prophylaxis the risk of post-
transplantation hepatitis B is over 80%.In this 
condition the use of antivirals before transplant 
(one  single  antiviral  in  the  case  of  wild  type 
virus, combined with a second one that is active 
on  the  mutants,  in  the  condition  of  drug 
resistance  with  active  replication),  associated Medit J Hemat Infect Dis 2010; 1(3); Open Journal System 
with  HBIG  after  surgery  (combined 
prophylaxis), is protective in more than 90% of 
patients
32,33.
b) HBsAg-negative/anti-HBc positive recipients: in 
absence  of prophylaxis  the  risk  of  sero-
reversion  after  transplantation  (de-novo 
hepatitis  B)  is  less  than  5%  from  naïve  liver 
donors  and  10-15%  from  anti-HBc  positive 
donors
19,34.
c) HBsAg-positive  donors:  the  risk  of  hepatitis  B 
transmission  from a HBsAg-positive donor is 
high, as the neutralizing effect of HBIG is very 
low    and  the  reappearance  of  HDV,  in  co-
infected recipients, is constant. In this particular 
condition  the  reactivation  of  hepatitis  would 
appear to be controlled by the combination of 
two antivirals in the long term
35.
d) HBsAg-negative/anti-HBc  positive  donors: in 
this  category  the  overall  risk  of  HBV 
transmission and hepatitis is high (33-78%), in 
the absence of prophylaxis, ranging from 70% 
in  naïve  to  10-15%  in  anti-core  recipients. 
Combined prophylaxis with lamivudine±HBIG 
controls  relapse  in  nearly  all  cases,  while 
personalized  prophylaxis  with  only  HBIG  or 
only lamivudine has been suggested in low risk 
recipients  (anti-core  positive)
34. Comparative 
studies are not available in this setting.
Recommendations in relation to recipients: In all 
HBsAg-positive  carriers  there  is  an  indication  to 
universal  prophylaxis  post-surgery  according  to 
their original virological condition:
a)  in  active  carriers,  therapybefore  surgery  is 
indicated (with one or two antivirals in cases of 
YMDD mutants), with the aim of achieving the 
reduction  of  HBV  DNA  below  the  limit  of 
sensitive HBV assays or at least below < 20,000 
IU/ml,  in  association  with  combined 
prophylaxis (HBIG and one or two antivirals, as
previously  reported)  in  the  post-operative 
period;
b) in inactive carriers, the role of therapy before 
surgery  remains  controversial  because  of  the 
high  (>  80%)  protective  effect  of  post-
transplantation combined prophylaxis. In these 
subjects a preventive reduction of HBV DNA 
before  surgery  might  not  be  necessary,  with 
regard to the minimal residual risk, but it  could 
be desirable in order to save HBIG in the long 
term  after  liver  transplantation.  Likewise, 
insubjects  with  spontaneous  undetectable 
viremia (PCR-negative)  or with  levels around 
the  limit  of  detectability  (<  2,000  IU/ml), 
especially  if  co-infected  with  HDV,  the 
protective power of just HBIG seems to be very 
high. Although also in this conditionthe use of 
the  combined  prophylaxis  after  liver 
transplantation permits a considerable saving of 
HBIG in the long term.
c) in  HBsAg-negative/anti-HBc  positive 
recipients,  in  analogy  with  what  has  been 
described in the other transplants, albeit in the 
presence of serum and intra-hepatic evidence of 
re-infection  by  HBV  in  the  post-transplant 
period, the risk of sero-reversion is practically 
nil
36-37  and  so  there  is  no  indication  for  any 
prophylaxis,  but  only  the  monitoring  of  the 
HBsAg.
Recommendations in relation to donors: The use 
of organs from HBsAg-positive donors should be 
considered  only  in  conditions  of  emergency, 
avoiding their use in HDV recipients. In this setting 
the use of universal prophylaxis with two antivirals 
post-transplant could permit the control of clinical 
hepatitis B recurrence in the long term. Instead the 
use  of  livers  from  HBsAg-negative/anti-HBc 
positive donors is justified by the shortage of organs 
but requires the adherence to specific rules in the 
Donor/Recipient  match  (preferential  allocation  of 
anti-HBc  positive  grafts  to  HBsAg  positive  or 
negative/anti-HBc  positive  recipients)  and  the 
activation  of  universal  prophylaxis  with  
lamivudine±HBIG. 
Rheumatology
Background: Reports regarding the reactivation of 
HBV  in  the  rheumatology  setting  are  episodic, 
during  the  course  of  hydroxychlorochine, 
azathioprine, methotrexate and anti-Tumor Necrosis 
factor  (TNF).  The  few  data  available  all  refer  to 
active  and  inactive  HBsAg  carriers.  However, 
reports  on  anti-CD20  derive  from  hematological 
experience, and like in hematology the risk of HBV 
reactivation  in  the  rheumatology  setting  would 
appear to be linked both to the phase of immuno-
suppression and to that of immuno-reconstitution.
In  the  meantime  no  reactivations  have  been 
reported  in  the few  HbsAg-positive  rheumatology 
patients  undergoing  universal  prophylaxis  with 
lamivudine during immunosuppressive therapy.
38-41
In the absence of data two risk categories have 
been  identifiedwith  regard  to  the  type  and  to  the 
degree of immunosuppression: a) high risk of HBV 
reactivationin  patients  undergoing  the  following 
therapy:  anti-TNF  antibodies,  medium  to  high 
dosage  steroids  (>7.5  mg/die)  for  prolonged 
periods,  immunosuppressors  such  as 
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cyclosporine,  tacrolimus,  azathioprine  and 
mycophenolate. Although cases of viral reactivation 
have  not  yet  been  described  in  rheumatology 
patients  undergoing  treatment  with  anti-CD20 
antibodies, the  data which have emerged in  other 
specialist circles suggest the inclusion in this group 
of these and other monoclonals; b) low risk of HBV 
reactivation in patients treated with steroids at <7.5 
mg/die, sulfasalazine and hydroxychlorochine
1.
Recommendations  from  the  Italian  guidelines: 
Among  HBsAg-positive  patients, therapy  is 
indicated  in  active  carriers  and  universal 
prophylaxis  with  a  NA  is  suggested  in  inactive 
carriers  who  underwent  high-risk  treatment, 
especially if they are subjects with manifestations of 
chronic liver disease due to the previous activity of 
HBV or other causes. Finally, in inactive HBsAg-
carriers  treated  with  low  risk  therapies  and  in 
HbsAg-negative/  anti-HBc  positive  subjects  the 
proposal  is  a  strategy  of  monitoring,with  the 
activation of therapy or targeted prophylaxis in the 
case  of  viral  reactivation  (HBV  DNA  >  20,000 
IU/ml) or sero-reversion, respectively.
Prophylaxis should be started 2-4 weeks before 
the  immunosuppressive  therapy,  if  possible,  and 
continued for at least 6-12 months afterwards (i.e. 
after  immunosuppressive  therapy  has  been 
suspended).  Hematology  literature  advises 
particular  caution  in  suspending  prophylaxis, 
especially in subjects treated with repeated cycles of 
monoclonal antibodies.
Peculiar  conditions in  the  rheumatology  setting: 
Anti-HBV  vaccination  in  rheumatology  patients 
remains  controversial  and  its  cost/benefit  ratio 
should be carefully assessed in groups particularly 
at  risk  of  HBV  (for  example  those  living  with 
HBsAg-positive individuals or health workers).
Panarteritis nodosa (PAN) is a rare necrotizing 
vasculitis  that  affects  small  and  medium-sized 
arteries  which  presents,  at  least  in  a  portion  of 
cases, a pathogenic correlation with HBV infection. 
In  the  treatment  of  HBV-related  PAN,  the 
immunosuppressive therapy (which also poses the 
question of an uncontrolled activation of the virus) 
should be associated with an antiviral therapy (in 
active carriers) or universal prophylaxis (in inactive 
carriers) to repress viral replication. In this regard 
single  cases  and  observational studies  with  small 
numbers of cases have documented the efficacy of 
interferon (IFN) and lamivudine.
HIV
Background:  Cirrhosis  and  liver  cancer  are  the 
second  cause of death worldwide in  HIV  carriers 
(3-4  million),  9%  of  whom  have  HBV  infection. 
Co-infection with HIV increases the rate of chronic 
HBV  infection,  reduces  the  annual  rate  of 
seroconversion to antiHBe and to antiHBs and may 
be linked to the reactivation of the occult infection
in  HBsAg-negative  subjects  in  the  presence  of 
severe immunodepletion.
Moreover  co-infection  with  HIV  accelerates 
progression  towards  cirrhosis  and  liver 
decompensation  and  reduces  survival  in 
decompensated cirrhotics. Therefore mortality due 
to liver disease in those co-infected with HIV-HBV 
is  higher  compared  to  subjects  with  just  HBV 
infection
43-44.
Recommendations from the Italian guidelines:
A.  Patients  undergoing  Anti-Retroviral  viral 
Therapy (ART):  In  active  and  inactive 
carrierstherapy  and  universal  prophylaxis  with 
antivirals(utilizing the same NAs effective on HBV 
used  in  the  treatment  of  HIV  infection)  are 
indicated,  respectively.  In  HbsAg-negative/anti-
HBc  positive  subjects,  the  condition  of  occult 
carrier,  characterized  by  HBV  DNA  positivity  in 
serum and/ or in the liver, has been identified in 35-
90% of subjects with HIV co-infection using high 
sensitivity techniques, and only in 1% of cases with 
less sensitive techniques. Even in the presence of 
anecdotal  reports  of  reactivation  during 
immunodepletion  and/or  of  suspension  of 
lamivudine, the risk of sero-reversion appears to be 
very  low  (0.23/100  patients/year)  and  it  doesnot 
therefore  justify  any  prophylaxis  but  only 
monitoring
44.
B.  Patients  who  do  not  require  ART: In  active 
carriers  therapy  with  interferons  or  antivirals  is 
indicated.  In  these  subjects  treatment  should 
preferably  be  administered  using  drugs  which  do 
not have any effect on HIV and which do not, in the 
future,  induce  resistance  to  ART    Instead,  in 
inactive carriers and in anti-HBc positive subjects 
monitoring of HBV DNA or HBsAg, respectively, 
is  recommended,  with  activation  of  therapy  or 
targeted prophylaxis in the case of reactivation or 
sero-reversion.
Conclusions: Literature on hepatitis B in immuno-
compromised    patients  is  very  heterogeneous.  It 
refers  mainly  to  the  pre-NAs  era  and  the  period 
prior to the introduction of the modern techniques 
of determination and quantification of the viremia, 
which raises many doubts and difficulties about the 
interpretation  of  the  studies  and  leaves  several 
aspects still a matter of debate. This encourages a 
network of communication and studies, in order to Medit J Hemat Infect Dis 2010; 1(3); Open Journal System 
better define the natural history, the potential risk of 
hepatitis B and the results of the various strategies 
proposed in the management.
Even  in  the  light  of  such  premises  today  it 
appears  to  be  justified  to  propose  a  rational 
approach  to  the  problem  of  hepatitis  B  in 
immunocompromised  patients,  which  provides 
for:a)  screening  of  HBV    markers  in  all  subjects 
starting  immunosuppressive  therapies  and  the 
evaluation of their original liver condition (baseline; 
b) therapy of active carriers, preferably with third 
generation NAs; c) prophylaxis, preferentially with 
a  low-cost  NA,  of  inactive  carriers  and  anti-HBc 
positive  patients  at  risk  (onco-hematologic  and 
BMT  patients);  c)  HBV  DNA  (in  inactive  overt 
carriers) or HBsAg (in anti-HBc positive subjects) 
monitoring of the remaining patients at low risk of 
reactivation.  Finally,  in  the  transplant  setting,  a 
precise  Donor/Recipient  matching  should  be 
considered.
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